PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common human malignancies worldwide with very poor prognosis. Resistance to targeted therapeutic drugs such as sorafenib remains one of the major challenges in clinical treatment. In the present study, PARP1 was found to be highly expressed in human...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Cancer
Asıl Yazarlar: Yang, Xiao-Dong, Kong, Fan-En, Qi, Ling, Lin, Jia-Xin, Yan, Qian, Loong, Jane Ho Chun, Xi, Shao-Yan, Zhao, Yue, Zhang, Yan, Yuan, Yun-Fei, Ma, Ning-Fang, Ma, Stephanie, Guan, Xin-Yuan, Liu, Ming
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2021
Konular:
Letter to the Editor
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7824946/
https://ncbi.nlm.nih.gov/pubmed/33485358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-021-01315-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller